An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

Abstract Objectives To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc). Methods In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquin...

Full description

Bibliographic Details
Main Authors: Roger Hesselstrand, Jörg H. W. Distler, Gabriela Riemekasten, Dirk M. Wuttge, Marie Törngren, Helén C. Nyhlén, Fredrik Andersson, Helena Eriksson, Birgitta Sparre, Helén Tuvesson, Oliver Distler
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Arthritis Research & Therapy
Subjects:
Systemic sclerosis
Clinical trial
Paquinimod
Skin fibrosis
Online Access:https://doi.org/10.1186/s13075-021-02573-0

Internet

https://doi.org/10.1186/s13075-021-02573-0

Similar Items